Key result
Virus-like particles (VLPs) against picornaviruses show promising immunogenicity, but translation into vaccine products requires further bioprocess development and analytical characterization.
This review highlights the potential and bioprocessing challenges of developing virus-like particle vaccines against picornaviruses.
Answers are grounded in this paper and cite their sources.
VLPs against picornaviruses require further development before clinical use; leaves open key bioprocess and analytical questions for vaccine translation.
Vaccination has been the most effective and economical way of combating the spread of infectious disease. Virus-like particles (VLPs) against human and animal diseases caused by picornaviruses are actively being researched and developed as potential vaccines. Promising immunogenicity and protective efficacy data has been reported for VLPs produced using various expression systems. The translation of these VLPs into vaccine products requires further bioprocess development, underpinned by advanced analytical VLP characterization techniques. We overview approaches taken to effectively produce and purify these multiprotein VLPs to achieve the desired immune responses. The opportunities for developing VLP bioprocessing technologies for cost-effective and efficient vaccine manufacturing are highlighted.
No takes yet. Share an insight, caveat, or question.
Somasundaram et al. (2015) conducted a review in Infectious diseases caused by picornaviruses. Virus-like particles (VLPs) vaccines was evaluated. Virus-like particles (VLPs) against picornaviruses show promising immunogenicity, but translation into vaccine products requires further bioprocess development and analytical characterization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: